GREENWOOD VILLAGE, Colo., Feb. 27, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has priced an underwritten public offering of 8,500,000 shares of its common stock. The shares will be sold at a price to the public of $7.00 per share for gross proceeds of $59.5 million.
Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering.
Net proceeds, after underwriting discounts and commissions and other estimated fees and expenses payable by Ampio Pharmaceuticals, Inc., will be approximately $55 million.Ampio Pharmaceuticals, Inc. intends to use the net proceeds of the offering for working capital and for general corporate purposes, including continuation and completion of our Ampion and Optina clinical trials, submission of a BLA related to Ampion and a NDA relating to Optina, and equipment acquisition and related outfitting in connection with our manufacturing facility. In connection with the offering, Ampio Pharmaceuticals, Inc. has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. The securities described above are being offered by Ampio Pharmaceuticals, Inc. pursuant to shelf registration statements on Form S-3 (File Nos. 333-177116 and 333-193096) including base prospectuses, previously filed and declared effective by the Securities and Exchange Commission (SEC). The securities may be offered only by means of a prospectus. A preliminary prospectus supplement related to the offering was filed with the SEC on February 24, 2014 and a final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus supplement, when available, also may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at email@example.com, or by phone at (800) 831-9146; and Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by email at Prospectus_Department@jefferies.com, or by phone at (877) 547-6340. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV